Colombian health Minister Alejandro Gaviria is expected to formally request market regulators SIC to remove the exclusivity license granted to drug-makers Novartis for a legal monopoly on the sale of Gilvec Imatin B, a drug used to treat various kinds of cancer and leukemia. In doing so, the minister revives an old argument between Colombian health authorities and the Swiss multinational over its Intellectual Property rights.
Featured News
UK Competition Watchdog Eyes Potential Evri-DHL Merger Over Market Concerns
Jun 16, 2025 by
CPI
Apple Faces New EU Ultimatum Over Digital Markets Act Violations
Jun 16, 2025 by
CPI
UK Competition Regulator Reviews Need for Google Ad Restrictions
Jun 15, 2025 by
CPI
Pork Producers Seek Immediate Appeal in Price-Fixing Case
Jun 15, 2025 by
CPI
Crypto Heavyweights Close to EU Licenses Amid Regulatory Tensions
Jun 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros